María Victoria
Mateos Manteca
Profesora Titular de Universidad
![Foto de María Victoria](/img/nophoto.png)
![Foto de University of Melbourne](/img/noimage_org.png)
University of Melbourne
Melbourne, AustraliaPublications in collaboration with researchers from University of Melbourne (19)
2024
-
Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 6, pp. 358-363
2023
-
A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 4, pp. 711-722
-
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347
-
Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
Blood Advances, Vol. 7, Núm. 14, pp. 3739-3748
2022
-
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
The Lancet Oncology, Vol. 23, Núm. 1, pp. 65-76
-
Corrigendum to “P-137: ITHACA, A Randomized Multicenter Phase 3 Study of Isatuximab in Combination With Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Safety Run-in Preliminary Results” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S109- S110] (Clinical Lymphoma, Myeloma and Leukemia (2021) 21(S2) (S1–S189), (S2152265021X00122))
Clinical Lymphoma, Myeloma and Leukemia
-
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study
American Journal of Hematology
-
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
Blood, Vol. 139, Núm. 4, pp. 492-501
2021
-
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy
British Journal of Haematology
-
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
American Journal of Hematology, Vol. 96, Núm. 6, pp. 708-718
-
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Journal of Hematology and Oncology
-
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
American Journal of Hematology, Vol. 96, Núm. 9, pp. 1120-1130
-
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118
2020
-
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
The Lancet, Vol. 396, Núm. 10245, pp. 186-197
-
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk
Journal of Hematology and Oncology, Vol. 13, Núm. 1
-
Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: The phase III TOURMALINE-MM4 trial
Journal of Clinical Oncology, Vol. 38, Núm. 34, pp. 4030-4041
-
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
The Lancet, Vol. 396, Núm. 10262, pp. 1563-1573
2018
-
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies
The Lancet Haematology, Vol. 5, Núm. 11, pp. e563-e598
-
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR
Haematologica, Vol. 103, Núm. 12, pp. 2079-2087